These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 25259549)

  • 1. Successful combined intratumoral immunotherapy of established murine mesotheliomas requires B-cell involvement.
    Krishnan S; Bakker E; Lee C; Kissick HT; Ireland DJ; Beilharz MW
    J Interferon Cytokine Res; 2015 Feb; 35(2):100-7. PubMed ID: 25259549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
    Jackaman C; Nelson DJ
    Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of immune suppression exerted by regulatory T-cells in subcutaneous AE17 murine mesothelioma.
    Kissick HT; Ireland DJ; Greay SJ; Beilharz MW
    J Interferon Cytokine Res; 2010 Nov; 30(11):829-34. PubMed ID: 20836714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40-activated B cells contribute to mesothelioma tumor regression.
    Jackaman C; Cornwall S; Graham PT; Nelson DJ
    Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
    Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
    Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
    Hegmans JP; Hemmes A; Aerts JG; Hoogsteden HC; Lambrecht BN
    Am J Respir Crit Care Med; 2005 May; 171(10):1168-77. PubMed ID: 15764728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
    Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
    Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined intratumoral regulatory T-cell depletion and transforming growth factor-β neutralization induces regression of established AE17 murine mesothelioma tumors.
    Kissick HT; Ireland DJ; Beilharz MW
    J Interferon Cytokine Res; 2009 Apr; 29(4):209-15. PubMed ID: 19203251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy of a murine B cell tumor with antibodies and F(ab')2 fragments against idiotypic determinants of its cell surface IgM.
    Perek Y; Hurwitz E; Burowski D; Haimovich J
    J Immunol; 1983 Sep; 131(3):1600-3. PubMed ID: 6604103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
    Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
    Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
    Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
    J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
    Gabrilovich DI; Ishida T; Nadaf S; Ohm JE; Carbone DP
    Clin Cancer Res; 1999 Oct; 5(10):2963-70. PubMed ID: 10537366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-12 induces an effective antitumor response in malignant mesothelioma.
    Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Scott B; Robinson BW
    Am J Respir Cell Mol Biol; 1998 Nov; 19(5):738-46. PubMed ID: 9806738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site.
    Jackaman C; Lew AM; Zhan Y; Allan JE; Koloska B; Graham PT; Robinson BW; Nelson DJ
    Int Immunol; 2008 Nov; 20(11):1467-79. PubMed ID: 18824504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma.
    Wu L; Yun Z; Tagawa T; De la Maza L; Wu MO; Yu J; Zhao Y; de Perrot M
    Cancer Immunol Immunother; 2014 Dec; 63(12):1285-96. PubMed ID: 25183171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mature B cells are critical to T-cell-mediated tumor immunity induced by an agonist anti-GITR monoclonal antibody.
    Zhou P; Qiu J; L'Italien L; Gu D; Hodges D; Chao CC; Schebye XM
    J Immunother; 2010 Oct; 33(8):789-97. PubMed ID: 20842058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.